Table 1.
Patient characteristics (CIS–CDMS vs CIS–CIS patients)
| CIS patients (n = 250) | CIS–CDMS (n = 114) | CIS–CIS (n = 136) | p valuea | |
|---|---|---|---|---|
| Female sex, no. (%) | 189 (75.6) | 92 (80.7) | 97 (71.3) | 0.09 |
| Age, mean (SD), years | 33.6 (8.3) | 32.6 (7.9) | 34.5 (8.5) | 0.07 |
| Follow-up time, mean (SD), months | 58.1 (35.9) | 72.3 (30.4) | 46.3 (36.0) | < 0.01 |
| Type of clinical onset, no. (%) | ||||
| Optic nerve | 88 (35.2) | 33 (28.9) | 55 (40.4) | 0.06 |
| Spinal cord | 90 (36.0) | 45 (39.5) | 45 (33.1) | 0.30 |
| Other localization | 72 (28.8) | 36 (31.6) | 36 (26.5) | 0.37 |
| OCB, (> 1 band), (%) | 113 (73.9) | 63 (81.8) | 50 (65.8) | 0.02 |
| ≥ 9 lesions on T2-weighted images, no. (%) | 96 (38.6) | 53 (46.9) | 43 (31.6) | 0.01 |
| DMT at time of CIS, no. (%) | 57 (22.8) | 26 (22.8) | 31 (22.8) | 1.00 |
| Smoking at time of CIS, no. (%) | 79 (31.6) | 53 (46.5) | 26 (19.1) | < 0.01 |
| Pack-years at time of CIS, median (IQR) | 1.0 (0.0–5.9) | 2.4 (0.0–9.5) | 0.0 (0.0–2.7) | < 0.01 |
CIS clinically isolated syndrome, CIS–CDMS patients who are diagnosed with CDMS during follow-up after CIS defined by Poser criteria, CIS–CIS not diagnosed with CDMS, na not applicable, OCB oligoclonal bands
aP value calculated between CIS–CDMS and CIS–CIS